Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Structure-based inhibitor design and validation : application to Plasmodium falciparum glutathione S-transferase
Dissertation (MSc (Bioinformatics))--University of Pretoria, 2008.
Saved in:
| Other Authors: | |
|---|---|
| Format: | Thesis |
| Published: |
University of Pretoria
2013
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613499393310720 |
|---|---|
| access_status_str | Open Access |
| author2 | Kenyon, C.P. |
| author_browse | Kenyon, C.P. |
| author_facet | Kenyon, C.P. |
| collection | Thesis |
| dc_rights_str_mv | © University of Pretoria 2006E562 / |
| description | Dissertation (MSc (Bioinformatics))--University of Pretoria, 2008. |
| format | Thesis |
| id | oai:repository.up.ac.za:2263/26485 |
| institution | University of Pretoria (South Africa) |
| last_indexed | 2026-06-10T12:37:07.296Z |
| license_str | Other — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository |
| publishDate | 2013 |
| publishDateRange | 2013 |
| publishDateSort | 2013 |
| publisher | University of Pretoria |
| publisherStr | University of Pretoria |
| record_format | dspace |
| source_str | UPSpace — University of Pretoria Institutional Repository |
| spelling | oai:repository.up.ac.za:2263/26485 Structure-based inhibitor design and validation : application to Plasmodium falciparum glutathione S-transferase Kenyon, C.P. Louw, Andre Joubert, Fourie mbotha@csir.co.za Botha, Maria Magdalena Malaria parasite Novel ligands Inhibitor UCTD Dissertation (MSc (Bioinformatics))--University of Pretoria, 2008. The primary aim of this study was to use a computational structure-based ligand design strategy in finding novel ligands that could act as inhibitors of PfGST as basis for future antimalarial drug development. Since there is only one PfGST isoenzyme present in the parasite and the architecture of the binding site differs significantly from its human counter part, PfGST is considered a highly attractive drug target. Inhibition of PfGST is expected to interfere at more than one metabolic site in synergy: it is likely to disrupt the glutathione-dependent detoxification process, which will lead to an increase in the cytotoxic peroxide concentration and most likely lead to an increase in the levels of ferriprotoporphyrin IX and hemin as well. S-hexyl glutathione was co-crystallized with PfGST (Harwaldt et al., 2004), consequently it was seen as one of the most important lead compounds in the development of PfGST inhibitors. The first step in the rational drug design strategy was to modify GTX, concentrating on its ability to bind competitively to the G site and the hydrocarbon chain protrudes into the H site as well. Considering the 3D structure of the enzyme, modifications to GTX were made by LUDI and NEWLEAD, resulting in a library of active site binding ligands ranked by AutoDock according to their ability to optimally bind to PfGST. Additionally, the ligands were ranked according to their affinity for binding to PfGST produced by AutoDock, LUDI and XScore. Once all the compounds were ranked by these in silico methods they were screened for acquisition or synthetic accessibility and those available were experimentally screened for activity against recombinantly expressed PfGST. Based on in silico predictions NDA was the best inhibitor followed by LAP and EDP. From the biological assay and Lineweaver-Burk analysis the order of inhibition was NDA as the best inhibitor tested, followed by LAP and EDP. EDP and LAP showed competitive inhibition but the inhibition constant values were signi_cantly lower than GTX. With respect to GSH and CDNB, NDA was found to be a non-competitive inhibitor. It was suggested therefore that NDA binds to a non-substrate Summary 93 binding site that may lead to conformational change of the enzyme and hence lead to a loss in enzyme activity. This data leads to the conclusion that the H site should be better exploited in order to find more potent inhibitors or non-substrate binding sites. It was concluded that the experimental results add confidence to the discriminative power of the structure-based ligand design strategy and that these inhibitors could form scaffolds for future antimalarial drug development. Biochemistry unrestricted 2013-09-07T06:03:08Z 2008-08-07 2013-09-07T06:03:08Z 2007-04-20 2008-08-07 2008-07-21 Dissertation a 2006E562 /ag http://hdl.handle.net/2263/26485 http://upetd.up.ac.za/thesis/available/etd-07212008-140458/ © University of Pretoria 2006E562 / application/pdf University of Pretoria |
| spellingShingle | Malaria parasite Novel ligands Inhibitor UCTD Structure-based inhibitor design and validation : application to Plasmodium falciparum glutathione S-transferase |
| title | Structure-based inhibitor design and validation : application to Plasmodium falciparum glutathione S-transferase |
| title_full | Structure-based inhibitor design and validation : application to Plasmodium falciparum glutathione S-transferase |
| title_fullStr | Structure-based inhibitor design and validation : application to Plasmodium falciparum glutathione S-transferase |
| title_full_unstemmed | Structure-based inhibitor design and validation : application to Plasmodium falciparum glutathione S-transferase |
| title_short | Structure-based inhibitor design and validation : application to Plasmodium falciparum glutathione S-transferase |
| title_sort | structure based inhibitor design and validation application to plasmodium falciparum glutathione s transferase |
| topic | Malaria parasite Novel ligands Inhibitor UCTD |
| url | http://hdl.handle.net/2263/26485 http://upetd.up.ac.za/thesis/available/etd-07212008-140458/ |